Clinical Trial Update: Switch Maintenance Pembrolizumab in Patients With NSCLC After First Line Platinum Doublet Chemotherapy [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating switch maintenance pembrolizumab after first-line platinum doublet chemotherapy in metastatic non-small cell lung cancer; results have …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)

Snippet

Sponsor: Bank of Cyprus Oncology Centre | Conditions: Metastatic Non Small Cell Lung Cancer | Phase 2 | Status: COMPLETED | Results posted: 2025-01-24